AT9283

DRUG2 trials

Sponsors

Astex Pharmaceuticals, Inc., NCIC Clinical Trials Group

Conditions

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Myeloid LeukemiaMultiple MyelomaMyelodysplastic SyndromesMyelofibrosis

Phase 1

Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias

TerminatedNCT00522990

Astex Pharmaceuticals, Inc.Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia +2

Start: 2006-09-30End: 2009-04-30Updated: 2024-08-02

Phase 2

A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma

CompletedNCT01145989

NCIC Clinical Trials GroupMultiple Myeloma

Start: 2011-02-15End: 2015-11-27Updated: 2023-08-04